KCT0007189Completed未知
A 12 week, Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of PS01 on Reducing Body Fat
Bobsnu0 sites120 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 120
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional Study
Eligibility Criteria
- Ages
- 19?(Year) to o Limit (—)
- Sex
- All
Inclusion Criteria
- •1) Adult male and female over the age of 19
- •2) Those with a body mass index (BMI) of 25 kg/m2 or more and less than 35 kg/m2 at Visits 1 and 2
- •3) A person who has consented to participate in this human application test before the start of the human application test and filled out the Informed Consent Form
Exclusion Criteria
- •1) Those currently receiving treatment for severe cardiovascular, immune, respiratory, hepatobiliary, renal and urinary systems, nervous system, musculoskeletal system, psychiatric, infectious disease, and malignant tumor
- •2) Drugs that affect body weight within 1 month (30 days) of visit 1 (obesity drugs (appetite suppressants, fat absorption inhibitors, GLP-1 receptor agonists, etc.), psychiatric drugs such as depression and schizophrenia, contraceptives, steroids Preparations, female hormones}, those who use health functional foods/supplements for weight control, herbal medicines, and formulas for weight control
- •3) Those who have received new beta-blockers or diuretics within 6 months of Visit 1, or those who are expected to change their dose during the trial period (However, if they are being administered without changing their dose from 6 months ago, they can participate)
- •4) Patients with uncontrolled hypertension (systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg, measurement standard after 10 minutes of rest for human subjects)
- •5) Diabetic patients whose glycated hemoglobin is 7.0% or higher or who are taking antidiabetic drugs (oral hypoglycemic agents, insulin, etc.)
- •6) Those with TSH of 0.1 µIU/mL or less or 10 µIU/mL or more
- •7) Those with GFR (Glomerular Filtration Rate) less than 45 mL/min
- •8) Those whose AST(GOT) or ALT(GPT) is 3 times or more of the normal upper limit of the implementing institution
- •9) Those who have problems with food intake for human application tests due to severe gastrointestinal disorders
- •10) People with alcohol use-induced disorders and central nervous system disorders
- •11) Those who are judged unable to exercise due to musculoskeletal disorders
- •12) Those who have had a weight change of 10% or more within 3 months based on visit 1
- •13) Those who participated in a commercial obesity program within 3 months of visit 1
- •14) Those who have participated in other interventional clinical trials (including human trials) within one month (30 days) of Visit 1, or who plan to participate in other interventional clinical trials (including human trials) after the start of this human trial
- •15) Those who are pregnant, lactating, or planning to become pregnant during this human application test period
- •16) Those who are sensitive to or allergic to the food ingredients for this human application test
- •17) Those who are judged inappropriate by the investigator for other reasons
Investigators
Similar Trials
Recruiting
Not Applicable
A 12 week, Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of PS01 on Reducing Body FatKCT0006619ovaKmed120
Completed
Not Applicable
A 12 week, Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of Lactobacillus plantarum LRCC5282 on Reducing Body FatKCT0008119otte Chilsung Beverage120
Completed
Unknown
Clinical Trial for the Evaluation of the Efficacy and Safety of ETB-F02 on Reducing Body FatEndocrine, nutritional and metabolic diseasesKCT0009233Enterobiome Inc.100
Recruiting
Unknown
A 12 week, Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Functionality and Safety of ETB-F03 on Atopic DermatitisDiseases of the skin and subcutaneous tissueKCT0009710Enterobiome Inc.100
Completed
Not Applicable
Clinical Trial for the Evaluation of the Efficacy and Safety of PVGL on Mild OsteoarthritisDiseases of the musculoskeletal system and connective tissueKCT0007603INE B146